Founders

renew founders

Michael Mendez
FOUNDER & CEO

Mike is a thought leader and innovator in the synthetic biology arena with 30 years experience in the biotechnology industry.

Read More

Scientific Advisory Board

Board
Joseph P. Noel, Ph.D. SCIENCE ADVISOR & CO-FOUNDER

Joseph P. Noel, Ph.D.
SCIENCE ADVISOR & CO-FOUNDER

Joe is a leading expert in prenylation and rational enzyme engineering.
He holds the Arthur and Julie Woodrow Chair at the Salk Institute.

Read More
Daniel R Deave

Daniel R. Deaver, PhD
SCIENCE ADVISOR

Dr. Deaver brings extensive expertise and experience to Renew in medicinal chemistry, non-clinical pharmacology, toxicology and the drug discovery, development and approval processes.

Read More

Nicholas Boulis, M.D.
SCIENCE ADVISOR

Nick is a world-renowned expert in neurosurgery and clinical neuroscience.
He is a co-founder
of Coda Biotherapeutics.

Read More
Ken Mackie, Ph.D. SCIENCE ADVISOR

Ken Mackie, M.D.
SCIENCE ADVISOR

Professor Mackie’s research is focused on cannabinoid receptors, the cell surface receptors responsible for most of the psychoactive and therapeutic actions.

Read More
Michael Burkart, Ph.D. SCIENCE ADVISOR & CO-FOUNDER

Michael Burkart, Ph.D.
SCIENCE ADVISOR & CO-FOUNDER

Michael is a natural product chemist
with a deep understanding
in Type III polyketide
and fatty acids biosynthesis.

Read More

Our Team

Our Team

Matthew Saunders, Ph.D.
DIRECTOR,
SCIENTIFIC RESEARCH

Dr. Saunders is experienced in drug target discovery and development in the pharmaceutical industry
and has also led
programs of strain development in major microalgae companies.

More…
Kyle Botsch LEAD SCIENTIST, MOLECULAR BIOLOGY

Kyle Botsch
LEAD SCIENTIST,
MOLECULAR BIOLOGY

Mr. Botsch has more than 10 years of biotechnology experience including research in protein-drug interactions and binding, cancer diagnostic assay development, and synthetic biology in bacteria, yeast, and algae.

More…

Tasha K. Altheide Ph.D., RESEARCH SCIENTIST

Tasha Altheide has over 15 years of experience with a variety of genetic systems, including enzyme engineering in microorganisms. Dr. Altheide is an author or co-author of 10 peer-reviewed scientific papers.

More…
Brian Kilduff VICE PRESIDENT BUSINESS DEVELOPMENT

Brian Kilduff
VICE PRESIDENT BUSINESS DEVELOPMENT

Brian Kilduff has more than 20 years operating in the risk finance and risk transfer business as an intermediary. Mr. Kilduff specializes in start-up management, with focus on business development, strategic and operational consulting.

More…
Larry Shushan DIRECTOR, CORPORATE COMMUNICATIONS

Larry Shushan
DIRECTOR,
CORPORATE
COMMUNICATIONS

Larry Shushan brings more than 30 years of experience in Corporate Communications and Public Affairs to Renew. He specializes in devising strategic communications to help companies accomplish their business objectives.

More…
Ruxandra Dwinell IN HOUSE LEGAL COUNSEL

Ruxandra Dwinell
LEGAL
COUNSEL

Ruxandra Dwinell has been a practicing attorney in the biotechnology and life sciences space for more than 18 years. She has worked in-house as corporate and transactional counsel for 11 years, including work in the field of synthetic biology.

More…
Avery Colorado Pahls BUSINESS ADVISOR, MEDICAL

Avery Colorado Pahls
BUSINESS ADVISOR,
MEDICAL

Avery Pahls Colorado
is a 20 year veteran of the medical startup industry with expertise in the branding, sales, publicity and introduction to market of new disruptive clinical technologies.

More…
Cary D. Nelson, M.D. MEDICAL DIRECTOR

Cary D. Nelson, M.D.
MEDICAL
DIRECTOR

Dr. Cary D. Nelson is a board certified family practitioner, aesthetic and medical concierge and nutraceutical advisor. He has been outspoken about the benefits of cannabinoids as pharmacological agents for the treatment of medical and psychiatric disorders.

More…

Our Platform

Platform

Renew has created a platform of “enzymatic chemistry” that employs custom enzymes to create a diverse pipeline of novel molecules as drug candidates.

Renew’s novel molecules are alkylresorcinol scaffold derivatives that naturally cross the blood-brain-barrier to be used to target Neuroinflammation indications.

Key Features

A pipeline of candidate drug molecules that naturally pass the blood-brain-barrier to engage receptors in the brain.
Enzyme Engineering
Capabilities of structure-based enzyme engineering to improve targeted biochemical processes and derived compounds.
Key Factors
Ability to control and improve
enzymatic prenylation
to create a diversity of
novel molecules.
Fermentation Process
Enzymatic platform that is amenable to large–scale production for pharmaceutical purposes.
login for more
Intellectual Property

Intellectual Property

Renew’s portfolio includes both new and licensed intellectual property and technological capabilities.
This portfolio enables Renew to engineer enzymes to create a prolific pipeline of proprietary derivative molecules for pharmaceutical drug development.

FOR MORE INFORMATION ON RENEWS PATENTS, KNOW-HOW AND TRADE SECRETS CLICK HERE:
login for more
Next Gen Cannabinoids for Clinical Neurology

Contact Us

General Inquiries: info@renewbiopharma.com

Press Inquiries: press@renewbiopharma.com

Contact Us